Inventor

Qi Zeng

Inventor
Singapore, SG

Overview

21→
Patents
2006–2021
Patent span
Chemistry
Primary field (CPC C)

Patents· 21 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations16%
A61KPreparations for medical, dental or toiletry purposes10%
C07KPeptides10%
C12NMicroorganisms or enzymes9%
G01NInvestigating or analysing materials by determining their chemical or physical properties7%
C07DHeterocyclic compounds6%
G06FElectric digital data processing4%
H01RElectrically-conductive connections4%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%
G01SRadio direction-finding3%
PatentTitleYear
11,000,956Gripping system202111,000,912Automatic solder paste feeding system202110,999,961Positioning device202110,933,460Wire processing apparatus202110,776,650Method and apparatus for video surveillance202010,659,727Device and method for transmitting video signals, and system for playing video signals202010,643,476Auxiliary parking method, apparatus, and system202010,645,481Earphone control device, earphone and control method for earphone202010,467,137Apparatus, system, integrated circuit die, and method to determine when to bypass a second level cache when evicting modified data from a first level cache201910,423,540Apparatus, system, and method to determine a cache line in a first memory device to be evicted for an incoming cache line from a second memory device201910,258,676Polypeptide vaccine201910,174,126Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide20199,790,503'VHZ for diagnosis and treatment of cancer'20179,580,513'VHZ for diagnosis and treatment of cancers'20179,321,845'Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide'20168,889,683'Substituted quinoxalines as inhibitors of fatty acid binding protein'20148,765,388'VHZ for diagnosis and treatment of cancer'20148,715,674'Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide'20147,135,491'5-Aryltetrazole compounds and uses thereof'20067,087,631'Aryltetrazole compounds, and compositions thereof'20067,078,423'5-Aryltetrazole compounds, compositions thereof, and uses therefor'2006

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2006Based in North Andover, MA, US· patent location history
2014–2019Patents assigned to AGENCY SCIENCE TECH & RES (5)· patent assignee history
2014–2019Patents assigned to ZENG QI (5)· patent assignee history
2014–2019Based in Singapore, SG· patent location history
2019Based in Santa Clara, CA, US· patent location history
2020Patents assigned to BOE TECHNOLOGY GROUP CO LTD (4)· patent assignee history
2020Based in Beijing, CN· patent location history
2021Patents assigned to SHENZHEN AMI TECH CO LTD (4)· patent assignee history
2021Patents assigned to TYCO ELECTRONICS SHANGHAI CO LTD (4)· patent assignee history
2021Based in Shenzhen, CN· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
AGENCY SCIENCE TECH & RES52014–2019
ZENG QIself52014–2019
BOE TECHNOLOGY GROUP CO LTD42020
SHENZHEN AMI TECH CO LTD42021
TYCO ELECTRONICS SHANGHAI CO LTD42021
Locations
LocationPatentsSpan
Singapore, SG72014–2019
Beijing, CN42020
Shenzhen, CN32021
North Andover, Massachusetts, US32006
Santa Clara, California, US22019